BREAST CANCER

FDA approves sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for unresectable/metastatic triple-negative breast cancer.

FDA approves palbociclib plus trastuzumab, with/without pertuzumab, and endocrine therapy as maintenance for HR+, HER2+ advanced breast cancer.

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Erika Hamilton, MD, reviews the manageable safety profile of tucatinib plus HP maintenance therapy in HER2+ metastatic breast cancer from HER2CLIMB-05.

Dr Ajaz Khan of City of Hope shares key ASCO 2026 takeaways, including giredestrant, selpercatinib, ivonescimab, and the rise of ctDNA and AI in oncology.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.

Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.

ASCO 2026 highlights: KRAS signals, ADC‑immunotherapy momentum, and new TNBC/HER2 breakthroughs shaping next breast cancer trials.

VIKTORIA-1 shows gedatolisib regimens double PFS and cut hyperglycemia vs alpelisib in PIK3CA-mutant HR+/HER2– breast cancer.

Living in food deserts links to aggressive ctDNA mutations and shorter metastatic breast cancer survival, with the starkest survival gaps seen in Black patients.

FDA fast-tracks TER-2013, an oral AKT1-selective inhibitor, for HR+/HER2– advanced breast cancer with AKT/PI3K/PTEN alterations.

FDA clears automated PD-L1 22C3 testing on Dako Omnis for 4 more tumors, streamlining labs and guiding Keytruda therapy decisions.

Dr Tolaney discusses ASCENT-04 data, showing sacituzumab govitecan plus pembrolizumab improves PFS in 1L mTNBC across all Trop-2, tBRCA, and HER2 subgroups.

The FDA approved Lupin and Natco’s generic eribulin mesylate for pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.

Mabel Mardones, MD, discusses findings from the phase 3 perservERA trial presented at ASCO 2026.

"The VIKTORIA-1 trial validates the PAM pathway as a molecular driver in hormone receptor–positive, HER2-negative advanced breast cancer, regardless of PIK3CA mutation status," said Sara Hurvitz, MD.

“The results from this phase 3 study support iza-bren as a new standard of care for patients with pretreated metastatic triple-negative breast cancer,” said Jiong Wu, MD, PhD.

FDA fast-tracks oral SERD giredestrant for early ER+/HER2- breast cancer after phase 3 shows 30% fewer invasive recurrences.

"Sacituzumab govitecan plus pembrolizumab [led to] improvement in PFS2...despite the crossover design of the trial," said Eleonora Teplinsky, MD.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to prove prevention.

SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting quality of life.

Discover the final 7.8-year survival data from KEYNOTE-522 and see how adding pembrolizumab to chemotherapy drastically cuts recurrence for early TNBC.

"The key finding is that more axillary surgery in itself does not improve survival in these patients," said Jana de Boniface, MD, PhD.